Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) were down 2.9% on Tuesday . The stock traded as low as $14.11 and last traded at $14.11. Approximately 4,403 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 273,655 shares. The stock had previously closed at $14.53. Wall […]
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) Director David Hallal sold 1,171 shares of the business’s stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $19.51, for a total transaction of $22,846.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which […]
Analysts expect that iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) will report earnings of $0.82 per share for the current quarter, Zacks reports. Four analysts have made estimates for iTeos Therapeutics’ earnings, with the highest EPS estimate coming in at $1.07 and the lowest estimate coming in at $0.57. iTeos Therapeutics reported earnings per share […]
Analysts forecast that iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) will post earnings of $0.82 per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for iTeos Therapeutics’ earnings, with estimates ranging from $0.57 to $1.07. iTeos Therapeutics posted earnings per share of ($0.39) during the same quarter last […]
Wall Street analysts forecast that iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) will post sales of $63.30 million for the current fiscal quarter, according to Zacks. Four analysts have made estimates for iTeos Therapeutics’ earnings, with the lowest sales estimate coming in at $40.00 million and the highest estimate coming in at $78.10 million. The […]